Literature DB >> 19533421

Treatment of hormone-refractory prostate cancer, HRPC, remains challenging.

S John Weroha, J Fernando Quevedo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19533421     DOI： 10.1007/s12032-009-9249-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  3 in total

1.  Corticosteroid-induced inhibition of adrenal androgen production in selected patients with prostate cancer.

Authors:  H M Khandwala; R Vassilopoulou-Sellin; C J Logethetis; K E Friend
Journal:  Endocr Pract       Date:  2001 Jan-Feb       Impact factor: 3.443

2.  Efficacy of low-dose dexamethasone in castration-refractory prostate cancer.

Authors:  Ramachandran Venkitaraman; Karen Thomas; Robert A Huddart; Alan Horwich; David P Dearnaley; Chris C Parker
Journal:  BJU Int       Date:  2007-10-17       Impact factor: 5.588

3.  Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy.

Authors:  Thomas Nelius; Tobias Klatte; Werner de Riese; Allan Haynes; Stephanie Filleur
Journal:  Med Oncol       Date:  2009-04-14       Impact factor: 3.064
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.